Intra-articular administration of hylan G-F 20 in patients with symptomatic hip osteoarthritis: Tolerability and effectiveness in a large cohort study in clinical practice

Current Medical Research and Opinion

Volumn 24, Issue 5, 2008, Pages 1309-1316

  Migliore, Alberto ^a,b   Tormenta, Sandro ^a   Massafra, Umberto ^a   Bizzi, Emanuele ^a   Iannessi, Francesca ^a   Alimonti, Andrea ^a   Granata, Mauro ^c  

^a FATEBENEFRATELLI HOSPITAL   (Italy)

^b IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^c SAN FILIPPO NERI HOSPITAL   (Italy)

Author keywords

Hip; Hyaluronan; Hylan G F 20; Intra articular; Osteoarthritis; Ultrasound guided; Viscosupplementation

Indexed keywords

HYALURONIC ACID; PARACETAMOL;

ADULT; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECHOGRAPHY; FEMALE; FOLLOW UP; HIP OSTEOARTHRITIS; HUMAN; INJECTION SITE CONTUSION; INJECTION SITE PAIN; LEQUESNE INDEX; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL METHOD; OUTCOME ASSESSMENT; PREDICTIVE VALIDITY; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

AGED; AGED, 80 AND OVER; COHORT STUDIES; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYALURONIC ACID; INJECTIONS, INTRA-ARTICULAR; MALE; MIDDLE AGED; OSTEOARTHRITIS, HIP; PAIN MEASUREMENT; PROSPECTIVE STUDIES; RANGE OF MOTION, ARTICULAR; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER;

EID: 44349090895     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X291930     Document Type: Article

References (55)

1. Kuettner KE, Goldberg VM. Osteoarthritic disorders. Rosemont (IL): American Academy of Orthopedic Surgeons; 1995. p. xxi-xxv
2. Oliveria SA, Felson DT, Reed JI, et al. Incidence of symptomatic hand, hip, and knee osteoarthritis among patients in a health maintenance organization. Arthritis Rheum 1995;38:1134-41
3. Wilson MG, Michet CJ, Ilstrup DM, Melton LJ. Idiopathic symptomatic osteoarthritis of the hip and knee: a population-based incidence study. Mayo Clin Proc 1990;65:1214-21
4. Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005;64:669-81
5. Doherty M, Dougados M. Evidence-based management of osteoarthritis: practical issues relating to the data. Best Pract Res Clin Rheumatol 2001;15:517-25
6. Pencharz JN, Grigoriadis E, Jansz GF, Bombardier C. A critical appraisal of clinical practice guidelines for the treatment of lower-limb osteoarthritis. Arthritis Res 2002;4: 36-44
7. Balazs EA, Denlinger JL. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol Suppl 1993;39:3-9
8. Balazs EA. Physical chemistry of hyaluronic acid. Fed Proc 1958;17:1086-93
9. Pozo MA, Balazs EA, Belmonte C. Reduction of sensory responses to passive movements of inflamed knee joints by hylan a hyaluronan derivative. Exp Brain Res 1997;116:3-9
10. Bagga H, Burkhardt D, Sambrook P, March L. Long term effects of intra-articular hyaluronan on synovial fluid in osteoarthritis of the knee. J Rheumatol 2006;33:946-50
11. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and the knee: 2000 update. Arthritis Rheum 2000;43:1905-15
12. Pendleton A, Arden N, Dougados M, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2000;59:936-44
13. Raynauld JP, Torrance GW, Band PA, et al. A prospective, randomized, pragmatic health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthritis Cartilage 2002;10:506-17
14. Scale D, Wobig M, Wolpert W. Viscosupplementation of osteoarthritic knees with hylan: a treatment schedule study. Curr Ther Res 1994;55:220-32
15. Adams ME, Atkinson MH, Lussier AJ, et al. The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with nonsteroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthritis Cartilage 1995;3:213-25
16. Tamir E, Robinson D, Koren R, et al. Intra-articular hyaluronan injections for the treatment of osteoarthritis of the knee: a randomized, double blind, placebo controlled study. Clin Exp Rheumatol 2001;19:265-70
17. Kolarz G, Kotz R, Hochmayer I. Long-term benefits and repeated treatment cycles of intra-articular sodium hyaluronate (Hyalgan) in patients with osteoarthritis of the knee. Semin Arthritis Rheum 2003;32:310-9
18. Wobig M, Dickhut A, Maier R, Vetter G. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther 1998;20:410-23
19. Lussier A, Cividino AA, McFarlane CA, et al. Viscosupplementation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada. J Rheumatol 1996;23:1579-85
20. Dickson DJ, Hosie GJ. A double-blind, placebo-controlled comparison of hylan G-F 20 against diclofenac in knee osteoarthritis. J Clin Res 2001;4:41-52
21. Marshall KW. The current status of hylan therapy for the treatment of osteoarthritis. Today's Ther Trends 1997;15:99-108
22. Altman RD. Status of hyaluronan supplementation therapy in osteoarthritis. Curr Rheumatol Rep 2003;5:7-14
23. Lo GH, LaValley M, McAlindon T, Felson DT. Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. J Am Med Assoc 2003;290:3115-21
24. Arrich J, Piribauer F, Mad P, et al. Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: systematic review and meta-analysis. Can Med Assoc J 2005;172:1039-43
25. Wang C-T, Lin J, Chang C-J, et al. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. J Bone Joint Surg Am 2004;86A:538-45
26. Bellamy N, Campbell J, Robinson V, et al. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006;2:CD005321
27. Espallargues M, Pons JM. Efficacy and safety of viscosupplementation with hylan G-F 20 for the treatment of knee osteoarthritis: a systematic review. Int J Technol Assess Health Care 2003;19:41-56
28. Bragantini A, Molinaroli F. A pilot clinical evaluation of the treatment of hip osteoarthritis with hyaluronic acid. Curr Ther Res Clin Exp 1994;55:319-30
29. Brocq O, Tran G, Breuil U, et al. Hip osteoarthritis: short term efficacy and safety of viscosupplementation by hylan G-F 20. An open-label study in 22 patients. Joint Bone Spine 2002;69:388-91
30. Conrozier T, Bertin P, Mathieu P, et al. Intra-articular injections of hylan G-F 20 in patients with symptomatic hip osteoarthritis: an open-label, multicentre, pilot study. Clin Exp Rheumatol 2003;21:605-10
31. Migliore A, Martin Martin LS, Alimonti A, et al. Efficacy and safety of viscosupplementation by ultrasound-guided intra-articular injection in osteoarthritis of the hip. Osteoarthritis Cartilage 2003;11:305-6
32. Migliore A, Martin Martin LS, Valente C, et al. Intra-articular treatment with hylan G-F 20 (Synvisc) reduces NSAID consumption in patients with symptomatic osteoarthritis of the hip: preliminary clinical observations. Osteoporosis Int 2002;13:S20
33. Vad VB, Sakalkale D, Sculco TP, Wickiewicz TL. Role of hylan G-F 20 in treatment of osteoarthritis of the hip joint. Arch Phys Med Rehabil 2003;84:1224-6
34. Caglar-Yagci H, Unsal S, Yagci I, et al. Safety and efficacy of ultrasound-guided intra-articular hylan G-F 20 injection in osteoarthritis of the hip: a pilot study. Rheumatol Int 2005;25:341-4
35. Leopold SS, Battista V, Oliverio JA. Safety and efficacy of intraarticular hip injection using anatomic landmarks. Clin Orthop Relat Res 2001;391:192-7
36. Jackson DW, Evans NA, Thomas BM. Accuracy of needle placement into the intra-articular space of the knee. J Bone Joint Surg Am 2002;84A:1522-7
37. Qvistgaard E, Kristoffersen H, Terslev L, et al. Guidance by ultrasound of intra-articular injections in the knee and hip joints. Osteoarthritis Cartilage 2001;9:512-7
38. Migliore A, Tormenta S, Martin Martin LS, et al. Safety profile of 185 ultrasound-guided intra-articular injections for treatment of rheumatic diseases of the hip. Reumatismo 2004;56;104-9
39. Migliore A, Tormenta S, Martin Martin LS, et al. Open pilot study of ultrasound-guided intra-articular injection of hylan G-F 20 (Synvisc) in the treatment of symptomatic hip osteoarthritis. Clin Rheumatol 2005;24:285-9
40. Migliore A, Tormenta S, Martin Martin LS, et al. The symptomatic effects of intra-articular administration of hylan G-F 20 on osteoarthritis of the hip: clinical data of 6 months follow-up. Clin Rheumatol 2006;25:389-93
41. Altman R, Alarcon G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991;34:505-14
42. Kellgren JH, Lawrence JS. Radiological assessment of osteoarthrosis. Ann Rheum Dis 1957;16:494-502
43. Lequesne MG. The algofunctional indices for hip and knee osteoarthritis. J Rheumatol 1997;24:779-81
44. Imamura K, McKinnon M, Middleton R, Black N. Reliability of a comorbidity measure: the Index of Co-Existent Disease (ICED). J Clin Epidemiol 1997;50:1011-6
45. Tormenta S, Migliore A, Nardis P, et al. Ultrasound pattern in a cohort of 170 patients suffering from hip osteoarthritis. Osteoarthritis Cartilage 2004;12(B), S124, p. 305
46. Pavelka K. Treatment of pain in osteoarthritis. Eur J Pain 2000;4(Suppl A):23-30
47. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. J Am Med Assoc 2006;296:1633-44
48. Sturkenboom MC, Romano F, Simon G, et al. The iatrogenic costs of NSAID therapy: a population study. Arthritis Rheum 2002;47:132-40
49. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med 2000;160:777-84
50. Henry D. Non-steroidal anti-inflammatory drugs and the risk of development of congestive cardiac failure and functional renal impairment. Proceedings of the international conference on inflammopharmacology, San Francisco; 1997
51. Psaty BM, Furberg CD. Cox-2 inhibitors - lessons in drug safety. New Engl J Med 2005;352:1133-5
52. Goldberg VM, Coutts RD. Pseudoseptic reactions to hylan viscosupplementation: diagnosis and treatment. Clin Orthop Relat Res 2004;419:130-7
53. Kemper F, Gebhardt U, Meng T, Murray C. Tolerability and short-term effectiveness of hylan G-F 20 in 4253 patients with osteoarthritis of the knee in clinical practice. Curr Med Res Opin 2005;21:1261-9
54. Goldberg VM, Buckwalter JA. Hyaluronans in the treatment of osteoarthritis of the knee: evidence for disease-modifying activity. Osteoarthritis Cartilage 2005,13:216-24
55. Black N. Why we need observational studies to evaluate the effectiveness of health care. B Med J 1996;312(7040):1215-8